Kohsaka, S.; Okami, S.; Morita, N.; Yajima, T.
Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828. J. Clin. Med. 2023, 12, 2578.
https://doi.org/10.3390/jcm12072578
AMA Style
Kohsaka S, Okami S, Morita N, Yajima T.
Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828. Journal of Clinical Medicine. 2023; 12(7):2578.
https://doi.org/10.3390/jcm12072578
Chicago/Turabian Style
Kohsaka, Shun, Suguru Okami, Naru Morita, and Toshitaka Yajima.
2023. "Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828" Journal of Clinical Medicine 12, no. 7: 2578.
https://doi.org/10.3390/jcm12072578
APA Style
Kohsaka, S., Okami, S., Morita, N., & Yajima, T.
(2023). Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828. Journal of Clinical Medicine, 12(7), 2578.
https://doi.org/10.3390/jcm12072578